JP2006506361A - カルニチンおよび酸化防止ポリフェノールの治療用組合せ - Google Patents

カルニチンおよび酸化防止ポリフェノールの治療用組合せ Download PDF

Info

Publication number
JP2006506361A
JP2006506361A JP2004543656A JP2004543656A JP2006506361A JP 2006506361 A JP2006506361 A JP 2006506361A JP 2004543656 A JP2004543656 A JP 2004543656A JP 2004543656 A JP2004543656 A JP 2004543656A JP 2006506361 A JP2006506361 A JP 2006506361A
Authority
JP
Japan
Prior art keywords
carnitine
composition
acid
hydroxytyrosol
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004543656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506361A5 (enExample
Inventor
クレア，ロベルト
Original Assignee
クレアグリ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クレアグリ， インコーポレイテッド filed Critical クレアグリ， インコーポレイテッド
Publication of JP2006506361A publication Critical patent/JP2006506361A/ja
Publication of JP2006506361A5 publication Critical patent/JP2006506361A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2004543656A 2002-10-11 2003-10-10 カルニチンおよび酸化防止ポリフェノールの治療用組合せ Pending JP2006506361A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41783802P 2002-10-11 2002-10-11
PCT/US2003/032149 WO2004032873A2 (en) 2002-10-11 2003-10-10 Therapeutic combination of carnitine and antioxidant polyphenols

Publications (2)

Publication Number Publication Date
JP2006506361A true JP2006506361A (ja) 2006-02-23
JP2006506361A5 JP2006506361A5 (enExample) 2006-11-30

Family

ID=32094102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004543656A Pending JP2006506361A (ja) 2002-10-11 2003-10-10 カルニチンおよび酸化防止ポリフェノールの治療用組合せ

Country Status (6)

Country Link
US (1) US20040132821A1 (enExample)
EP (1) EP1558199A4 (enExample)
JP (1) JP2006506361A (enExample)
AU (1) AU2003279924A1 (enExample)
CA (1) CA2531056A1 (enExample)
WO (1) WO2004032873A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007330191A (ja) * 2006-06-16 2007-12-27 Nihon Yobo Igaku Kenkyusho:Kk メイラード反応を抑制する食品
JP2012524033A (ja) * 2009-04-17 2012-10-11 ディーエスエム アイピー アセッツ ビー．ブイ． ミトコンドリアの機能およびエネルギー生産を高めるためのヒドロキシチロソールの組合せ

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
WO2006053872A1 (en) * 2004-11-16 2006-05-26 Dsm Ip Assets B.V. The use of anti-oxidant compounds for muscle recovery
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
ES2261088B1 (es) * 2005-04-27 2007-12-01 Laboratorios Alcala Farma, S.L. Uso de hidroxitirosol en la prevencion y tratamiento del ictus cerebral isquemico.
RU2304964C2 (ru) * 2005-09-26 2007-08-27 Общество с ограниченной ответственностью "Экофарминвест" Способ лечения хронической сердечной недостаточности
US20090163579A1 (en) * 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
US20070231371A1 (en) 2006-02-01 2007-10-04 Nestec, S. A. Nutritional system and methods for increasing longevity
IT1391928B1 (it) * 2008-08-29 2012-02-02 Giellepi Chemicals S P A Integratore alimentare per il trattamento di neuropatie
US8796315B2 (en) 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
US8809311B2 (en) 2009-08-10 2014-08-19 Darlene McCord Nutritional supplements
EP2445483B1 (en) 2009-06-25 2017-04-26 McCord, Darlene Topical compositions and methods for wound care
WO2011109525A1 (en) * 2010-03-02 2011-09-09 Nox Technologies, Inc. Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP3706759B1 (en) * 2017-11-08 2023-11-15 Société des Produits Nestlé S.A. Homovanillyl alcohol (hva), hva isomer, methods of making compositions comprising such compounds, and methods using such compounds
CN113615833A (zh) * 2021-07-01 2021-11-09 泓博元生命科技（深圳）有限公司 一种用于改善心血管的线粒体营养素组合物及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1087483A (ja) * 1996-03-29 1998-04-07 Sigma Tau Ind Farmaceut Riunite Spa 神経系および心循環系に対する酸化ストレスにより惹起する疾患の予防および治療のためのｌ−カルニチンまたはその誘導体と抗酸化剤の使用
WO2001076579A1 (en) * 2000-04-06 2001-10-18 Perricone Nicholas V Treatment of skin damage using olive oil polyphenols
WO2001091589A1 (en) * 2000-05-30 2001-12-06 Sigma-Tau Healthscience S.P.A. Dietary supplement with antioxidant activity comprising an alkanoyl carnitine and a combination of polyphenols extracted from trees or shrubs
WO2002018310A1 (en) * 2000-09-01 2002-03-07 Creagri, Inc. Method of obtaining a hydroxytyrosol-rich composition from vegetation water

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6337320B1 (en) * 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
DE19824346A1 (de) * 1998-06-02 1999-12-09 Peter Schleicher Nahrungsergänzungsmittel
IT1299197B1 (it) * 1998-06-30 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante, antiproliferativa, energetica e atta a migliorare l'utilizzazione metabolica del glucosio.
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU2280900A (en) * 1998-12-22 2000-07-12 Unilever Plc Food compositions fortified with anti-oxidants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1087483A (ja) * 1996-03-29 1998-04-07 Sigma Tau Ind Farmaceut Riunite Spa 神経系および心循環系に対する酸化ストレスにより惹起する疾患の予防および治療のためのｌ−カルニチンまたはその誘導体と抗酸化剤の使用
WO2001076579A1 (en) * 2000-04-06 2001-10-18 Perricone Nicholas V Treatment of skin damage using olive oil polyphenols
WO2001091589A1 (en) * 2000-05-30 2001-12-06 Sigma-Tau Healthscience S.P.A. Dietary supplement with antioxidant activity comprising an alkanoyl carnitine and a combination of polyphenols extracted from trees or shrubs
WO2002018310A1 (en) * 2000-09-01 2002-03-07 Creagri, Inc. Method of obtaining a hydroxytyrosol-rich composition from vegetation water

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007330191A (ja) * 2006-06-16 2007-12-27 Nihon Yobo Igaku Kenkyusho:Kk メイラード反応を抑制する食品
JP2012524033A (ja) * 2009-04-17 2012-10-11 ディーエスエム アイピー アセッツ ビー．ブイ． ミトコンドリアの機能およびエネルギー生産を高めるためのヒドロキシチロソールの組合せ
US9446006B2 (en) 2009-04-17 2016-09-20 Dsm Ip Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production

Also Published As

Publication number Publication date
US20040132821A1 (en) 2004-07-08
WO2004032873A3 (en) 2004-07-29
CA2531056A1 (en) 2004-04-22
WO2004032873A2 (en) 2004-04-22
EP1558199A4 (en) 2006-06-28
AU2003279924A1 (en) 2004-05-04
EP1558199A2 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
US6365622B1 (en) Antioxidant composition comprising acetyl L-carnitine and α-lipoic acid
JP2006506361A (ja) カルニチンおよび酸化防止ポリフェノールの治療用組合せ
AU2017253109B2 (en) Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
CA2344893C (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
JP2020530843A (ja) 神経細胞損傷の治療のためのアミノ酸組成物
JP2014129394A (ja) アミノ酸組成物を含有する疲労防止剤
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
JP2785989B2 (ja) Ｌ―カルニチンおよびｌ―リジンを含有する薬剤および／または栄養剤用組成物
WO2006015774A1 (de) Physiologisch verträgliche zusammensetzung enthaltend alphaliponsaüre, kreatin und ein phospholipid
CA3195029A1 (en) Methods for improving exercise performance and endurance thereof
MXPA01002045A (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND&agr;-LIPOIC ACID
WO2006042666A1 (de) R-(+)-α-LIPONSÄURE ZUR PRÄVENTION VON DIABETES
EP1661562A1 (en) Sphingolipids in treatment and prevention of steatosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101102